[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"eosinophilia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:eosinophilia":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,48,72,95,130],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":4,"leadSponsor":44,"locationsCount":47},"100054447","activation-and-function-of-eosinophils-in-conditions-with-blood-or-tissue-eosinophilia-100054447",false,"NCT00001406","Activation and Function of Eosinophils in Conditions With Blood or Tissue Eosinophilia","Eosinophil Activation and Function in Parasitic Infections and Other Conditions With Increased Tissue or Peripheral Blood Eosinophilia in Humans","* INCLUSION CRITERIA:\n\nTo be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Stated willingness to comply with all study procedures and availability for the duration of the study\n2. Male or female, aged 1-100\n3. Ability of subject (or Legally Authorized Representative (LAR)) to understand and sign a written informed consent document\n\n   Eosinophilic Patients only:\n4. Documented peripheral blood count \\>1500\u002Fmm3, tissue eosinophilia (abnormal accumulation of eosinophils in the skin or other body tissues) or suspected eosinophilic end organ involvement\n5. Primary (non-NIH) physician for routine medical care\n\n   Relatives only:\n6. Extended family member of an eosinophilic participant on this protocol\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Any condition(s) or diagnosis, physical and\u002For psychological, that the investigator feels precludes the patient from participation in the study.\n\n   Relatives only:\n2. Females must not be pregnant","ALL","1 Year","100 Years",{"count":20,"type":21},800,"ESTIMATED","OBSERVATIONAL","This study will investigate how, why and under what conditions eosinophils (a type of white blood cell) become activated and will examine their function in immune reactions. Eosinophil counts often rise in response to allergies, asthma, and parasitic worm infections. They can also go up in uncommon autoimmune conditions and, rarely, in association with tumors. Elevated levels of these cells is called eosinophilia. Usually, eosinophilia causes no apparent symptoms, but in rare cases there may be local swelling and itching, allergic lung problems, heart disease or nerve damage caused by the release of toxic substances in these cells into body tissues.\n\nPatients 1 to 100 years of age with eosinophil counts greater than 750\u002Fml or an abnormal accumulation of eosinophils in the skin or body tissues may be eligible for this study. All participants will have a thorough medical history, physical examination and blood tests. Depending on the person's age and symptoms, other diagnostic tests may be done, including specialized studies of the eye, lungs, skin, bone marrow, nerves or heart. This is not a treatment study, and no experimental treatments will be offered. Patients who require treatment will receive standard medical care.\n\nCertain other procedures may be requested solely for research purposes. All participants will be asked to donate extra blood for laboratory studies investigating how immune cells and other immune substances in the blood act to stimulate a rise in eosinophils. In addition, some participants may undergo one or more of the following:\n\n* Annual Follow-up evaluations - Physical examinations and blood tests to evaluate changes in the patient's condition and eosinophil counts over time.\n* Bone marrow biopsy and aspiration will be recommended during the initial evaluation, and in certain patients at other times when it is important to look directly at the newly developing cells in the bone marrow. For this procedure an area of skin and bone is anesthetized with xylocaine (an anesthetic similar to that used by dentists), and a very sharp needle is used to sample the bone marrow for evaluation. Bone marrow biopsy and aspiration can have side effects of pain and\u002For bleeding into the skin and soft tissues at the site of the procedure. Rarely the area at the biopsy site can become infected, and is treated with antibiotics.\n* Genetic testing: Some of the blood drawn from you as part of this study will be used for genetic tests. Genetic tests can help researchers study how health or illness is passed on to you by your parents or from you to your children. Any genetic information collected or discovered about you or your family will be confidential.\n* Leukapheresis (only patients 18 years and older) to collect large numbers of certain cells - In this procedure, whole blood is collected through a needle placed in an arm vein. The blood circulates through a machine that separates it into its components. The white cells are then removed and the rest of the blood is returned to the body, either through the same needle used to draw the blood or through a second needle placed in the other arm....",[25,26,27,28,29],"Immune System Diseases","Eosinophilia","Helminthiasis","Hypersensitivity","Parasitic Disease",[31,32,33,34,35,36],"Eosinophils","Helminth Parasites","Hypereosinophilia","Allergy","Asthma","Natural History","RECRUITING","2026-06-03",{"date":40,"type":41},"2026-06-04","ACTUAL",{"date":43,"type":41},"1997-04-21",{"name":45,"class":46},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":4,"leadSponsor":71,"locationsCount":47},"100064634","a-longitudinal-study-of-familial-hypereosinophilia-fe-natural-history-and-markers-of-disease-progression-100064634","NCT00091871","A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Male or female, aged 1-100 years of age\n* Genetically related member of a previously identified family with FE\n* Ability of subject to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Any condition that the investigator feels put the subject at unacceptable risk for participation in the study\n* Pregnancy (in family members who do not have eosinophilia)",true,{"count":56,"type":21},50,"Eosinophils are a type of white blood cell. Elevated eosinophil levels can damage the heart, nerves, and other organs, in the syndrome known as hypereosinophilic syndrome (HES). Some individuals have a hereditary form of HES known as familial eosinophilia (FE). More research on the causation and mechanisms of HES is needed in order to design more effective and less toxic therapies.\n\nThis study will investigate FE and its genetic causes, damage mechanisms, and disease markers (such as blood test abnormalities). It will enroll approximately 50 individuals (both adults and children) from a previously studied family with FE. This is a long-term study of indefinite duration.\n\nParticipants will undergo yearly clinical examinations including medical history, physical examination, bloodwork, EKG, echocardiogram, and pulmonary function tests, with additional or more frequent examinations and tests as required. In addition, participants will donate blood and tissue for research purposes. Both adult and child participants will donate blood. At the initial evaluation, adult participants will donate bone marrow. During the study, some adult participants will also undergo a limited number of leukaopheresis sessions, in which blood is donated from one arm, the blood is separated into red blood cells and other components, and the red blood cells are returned into the donor's other arm.",[26,59],"Hypereosinophilic Syndrome",[33,61,62,63,36,64,65],"Eosinophil","Familial","Interleukin 5","Familial Hypereosinophilia","FE","2026-05-06",{"date":68,"type":41},"2026-05-07",{"date":70,"type":41},"2005-06-08",{"name":45,"class":46},{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":82,"conditions":83,"keywords":84,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":47},"100363892","natural-history-of-hypereosinophilia-and-hypereosinophilic-syndromes-100363892","NCT04018118","Natural History of Hypereosinophilia and Hypereosinophilic Syndromes","Study of Clinical Profiles of Patients Followed for Chronic Hypereosinophilia and\u002For Hypereosinophilic Syndrome by the Creation of a National Cohort","COHESION","Inclusion Criteria:\n\n* Men or Women of any age :\n* With the diagnosis criteria of hyperosinophlia OR hypereosinophilic syndrome OR specific organ eosinophilic disease according to the consensus conference of the International Cooperative Working Group on Eosinophil Disorders (ICOG-EO)\n* With an AEC \\> 1500\u002Fmm3 or organ damage related to the presence of eosinophils in the tissues or organs whatever the context (idiopathic, clonal or reactive, including drug-related, parasitic or allergic)\n* HES diagnosis since 2005\u002F01\u002F01\n* Patients socially insured\n* Patient who agreed to participate to the study, its proceedings and duration.\n\nExclusion Criteria:\n\n* Known HIV infection\n* Not socially insured\n* Person unable to receive a enlighten information\n* Person who refuse to sign the consent\n* Persons deprived of their liberty\n* Persons benefiting from a system of legal protection (tutelage \u002F guardianship)",{"count":81,"type":21},600,"Unexplained chronic hypereosinophilia (HE) and hypereosinophilic syndromes (HES) are heterogeneous regarding the organ involvements (heart, lungs, skin, .. or none), the evolutionary profiles, the response to treatments.\n\nUnderlying mechanisms are largely unknown and may associate genetic predisposing factors (germinal ? somatic?), environmental factors (alimentation, tobacco use, hormones, infections, ..) The COHESion study aims to study all clinical and biological characteristics of HE\u002FHES patients and their evolutionary profiles, with a focus on genetic factors and the mechanisms supporting transitory or persistant chronic HE\u002FHES (in absence of any well identified extrinsic trigger like drugs, parasitosis, ..)",[26,59],[26,33,59],"2026-02-18",{"date":87,"type":41},"2026-02-20",{"date":89,"type":41},"2019-05-06",{"date":91,"type":21},"2031-05",{"name":93,"class":94},"University Hospital, Lille","OTHER",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":102,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":105,"phases":106,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":129},"100347260","phase-2-ruxolitinib-in-treating-patients-with-hypereosinophilic-syndrome-or-primary-eosinophilic-disorders-100347260","NCT03801434","Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders","Phase 2 Study of Ruxolitinib in Idiopathic Hypereosinophilic Syndrome and Primary Eosinophilic Disorders","Inclusion Criteria:\n\n* Subject with idiopathic hypereosinophilic syndrome must meet the following:\n\n  * Has as at least 2 readings with an absolute eosinophil count \\>= 1,500\u002Fmm\\^3 in the preceding 3 months prior to starting ruxolitinib (one reading must be during the screening period).\n  * Dependent, intolerant or refractory to corticosteroids OR has relapsed\u002Frefractory disease to other therapy besides corticosteroids.\n  * Symptomatic from his\u002Fher disease OR has one or more signs of organ damage (assessed by the investigator as possibly-related to eosinophilia or biopsy-proven). This can include skin, lung, cardiac, central nervous system, liver, or gastrointestinal (GI) involvement, or evidence of symptomatic hepatic or splenic enlargement.\n* Subject with lymphocyte-variant hypereosinophilia must meet the following\n\n  * Has at least 2 readings with an absolute eosinophil count \\>= 1,500\u002Fmm\\^3 in the preceding 3 months prior to starting ruxolitinib (one reading must be during the screening period).\n  * Dependent, intolerant or refractory to corticosteroids\\* OR has relapsed\u002Frefractory disease to other therapy besides corticosteroids.\n  * Symptomatic from his\u002Fher disease OR has one or more signs of organ damage (assessed by the investigator as possibly-related to eosinophilia or biopsy-proven). This can include skin, lung, cardiac, central nervous system, liver, or GI involvement, or evidence of symptomatic hepatic or splenic enlargement\n  * Has abnormal T-lymphocyte immuno-phenotype by flow cytometry.\n* Subject with chronic eosinophilic leukemia, not otherwise specified (CEL,NOS) must meet the following\n\n  * Has at least 2 readings with an absolute eosinophil count \\>= 500\u002Fmm\\^3 in the preceding 3 months prior to starting ruxolitinib (one reading must be during the screening period).\n  * Newly-diagnosed OR receiving corticosteroids OR has relapsed\u002Frefractory disease to any therapy besides corticosteroids.\n  * Has increased blasts in the blood or bone marrow (\\> 5% and \\\u003C 20%), and\u002For a clonal cytogenetic or molecular abnormality\n\n    * Subjects with JAK2 mutations are included within this group.\n* Subject with JAK2-rearranged eosinophilic neoplasm must meet the following\n\n  * Has at least 2 readings with an absolute eosinophil count \\>= 500\u002Fmm\\^3 in the preceding 3 months prior to starting ruxolitinib (one reading must be during the screening period).\n  * Newly-diagnosed OR receiving corticosteroids OR has relapsed\u002Frefractory disease to any therapy besides corticosteroids.\n\n    * This group includes subjects with PCM1-JAK2, BCR-JAK2, ETV6-JAK2 or other JAK2 rearrangements.\n* If receiving corticosteroids, must be a stable dose for \\>= 28 days prior to Day 1 (unstable dosing not eligible).\n* Eastern Cooperative Oncology Group (ECOG) performance status =\\\u003C 3.\n* Willing and able to review and execute informed consent (legally-authorized consent acceptable).\n\nExclusion Criteria:\n\n* Active life-threatening complication(s) from underlying eosinophilic disease (i.e., leukostasis; acute thromboembolic disease including central nervous system (CNS) involvement; severe pulmonary or cardiac dysfunction). Stabilization of acute, life-threatening eosinophil-related co-morbidities will allow enrollment of the patient.\n* World Health Organization (WHO)-defined myeloid neoplasm associated with eosinophilia other than CEL NOS and JAK2 rearranged neoplasms (e.g., myelodysplastic syndrome (MDS); myeloproliferative neoplasms (MPN); MDS\u002FMPN overlap disorders; and systemic mastocytosis (SM).\n* Reactive hypereosinophilia due to connective tissue disease, sarcoidosis or eosinophilic granulomatosis with polyangiitis.\n* Organ-restricted ?tissue? eosinophilia with the absence of peripheral eosinophilia in the blood.\n* Invasive malignancy over the previous 2 years except treated early stage carcinomas of the skin, completely resected intraepithelial carcinoma of the cervix, and completely resected papillary thyroid and follicular thyroid cancers.\n* Myeloid or lymphoid neoplasm with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1.\n* Anticipated to receive a hematopoietic stem cell transplant within the first 6 months of treatment on trial.\n* Major surgery within 4 weeks prior to entering the study.\n* Life expectancy of \\\u003C 6 months.\n* Known diagnosis of human immunodeficiency virus (HIV).\n* Known diagnosis of chronic active hepatitis B or C (viral testing is not required). Subjects with a known history of hepatitis B and\u002For C are allowed on trial if at the time of enrollment, the virus is not active and undetected (testing required if there is a known history), and such patients are not actively receiving antiviral treatment specific for hepatitis B and\u002For C.\n* Clinically serious infections requiring ongoing antibiotic therapy.\n* Parasitic infection diagnosed within 24 weeks prior to enrollment.\n* Platelet count =\\\u003C 25 x 10\\^9\u002FL at baseline.\n* Alanine aminotransferase (ALT)\u002Fserum glutamate pyruvate transaminase (SGPT) \\> 4 x upper limit of normal (ULN) or direct bilirubin \\> 4 x ULN (if considered to be unrelated to the underlying eosinophilic disorder).\n* End-stage renal function (creatinine clearance \\[CrCl\\] \\\u003C 15 mL\u002Fmin or glomerular filtration rate \\[GFR\\] \\\u003C 15 mL\u002Fmin) regardless of whether hemodialysis is required.\n* Use of investigational or commercial therapies with the intent to treat the underlying eosinophilic disorder within 28 days of study start, including interferon; imatinib; alemtuzumab; cyclosporine; methotrexate; mepolizumab; benralizumab; or other antibody therapies.\n* Use of hydroxyurea within 7 days of study start.\n* Prior therapy with ruxolitinib or other JAK inhibitors.\n* Previous allergic reactions to JAK inhibitors or excipients.\n* Unwilling to commit to abstinence from heterosexual contact or agree to use and comply with highly effective contraception, 28 days prior to starting study drug, during the treatment period and for 12 weeks after discontinuation of study treatment.\n* Females of childbearing potential who have a positive pregnancy test (urine or serum) during screening period.","18 Years",{"count":104,"type":21},10,"INTERVENTIONAL",[107],"PHASE2","This phase II trial studies how well ruxolitinib works in treating patients with hypereosinophilic syndrome or primary eosinophilic disorders.",[110,111,112,113,114,115,26,116,59,117,118,119],"BCR-JAK2 Fusion Protein Expression","Blasts 20 Percent or Less of Peripheral Blood White Cells","Blasts More Than 5 Percent of Bone Marrow Nucleated Cells","Blasts More Than 5 Percent of Peripheral Blood White Cells","Blasts Under 20 Percent of Bone Marrow Nucleated Cells","Chronic Eosinophilic Leukemia, Not Otherwise Specified","Hepatomegaly","JAK2 Gene Mutation","Splenomegaly","TEL-JAK2 Fusion Protein Expression","2025-12-20",{"date":122,"type":41},"2025-12-23",{"date":124,"type":41},"2019-11-15",{"date":126,"type":21},"2028-12-30",{"name":128,"class":94},"William Shomali",4,{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":26,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":16,"minAge":102,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":105,"phases":139,"briefSummary":141,"conditions":142,"keywords":143,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":47},"100536518","specific-versus-empirical-anthelminthic-treatment-in-eosinophilia-100536518","NCT06265870","Specific Versus Empirical Anthelminthic Treatment in Eosinophilia","Comparison of Outcome Between Specific Anthelminthic Treatment According to Test Results and Empirical Anthelminthic Treatment in Eosinophilic Patient","Inclusion Criteria:\n\n* Participants who come for check-ups at general practitioner, primary care unit, and Srivejchavat Premium Center have an absolute eosinophil count greater than 500 cells\u002Fmicroliter with a white blood cell count less than 10,000 cells\u002Fmicroliter.\n* Age at least 18 years old\n* Consent to participate in research\n\nExclusion Criteria:\n\n* Having any characteristics that need urgent care 1.1 Having history of unintended significant weight loss is defined as the loss of body weight exceeding 10% within a span of six months without deliberate attention.\n\n1.2 Physical examination revealed a body temperature equal to or greater than 37.8 degrees Celsius, lymphadenopathy or hepatosplenomegaly.\n\n1.3 CBC revealed blast cell\n\n* Receiving anthelminthic drug within 6 months\n* Underlying cancer (active stage), HIV, HBV, HCV, collagen vascular disease, active TB\n* Allergy to albendazole, ivermectin, or metronidazole\n* Pregnancy or lactation\n* Serum transaminase higher than 2 times of upper normal limit\n* Taking medications that may induce eosinophilia within the past three months, such as herbal supplements, NSAIDs, Salicylic acid, Carbamazepine, Colchicine, Nitrofurantoin, Dapsone, or Minocycline, was reported.",{"count":138,"type":21},700,[140],"NA","There are a few guidelines recommend about management of eosinophilia worldwide, most of guielines recommend a thorough history-taking and physical examination. Subsequently, investigations are requested based on suspected causes. In cases where parasite infection is suspected, particularly in developing countries, stool microscopy and serology are recommended. However, limitations such as low sensitivity of stool microscopy, the inconvenience of collecting multiple stool samples, and the high cost and unavailability of serology may arise. Consequently, some physicians opt for empiric anthelminthic regimens in managing eosinophilic patients, even without stool tests or if stool test results are normal. If subsequent complete blood count (CBC) results show a recovery of absolute eosinophil count, it is assumed that eosinophilia was caused by a parasite infection. While some studies demonstrate the efficacy and simplicity of this approach, there is a risk of overestimating parasite infection in eosinophilic patients, potential adverse drug reactions from unnecessary anthelminthic treatment, and the possibility of drug resistance due to inappropriate dosing. To address this gap, no study has yet compared the efficacy between specific anthelminthic treatment based on test results and empirical anthelminthic treatment in eosinophilic patients. Therefore, the investigators are conducting this study.",[26],[144,145,146,147],"eosinophilia","anthelminthic drugs","empirical treatment","stool examination","2024-09-22",{"date":150,"type":41},"2024-09-24",{"date":152,"type":41},"2024-05-01",{"date":154,"type":21},"2025-12-31",{"name":156,"class":94},"Prince of Songkla University"]